Pantoprazole + domperidone


Full Prescribing Info
Dosage/Direction for Use

Oral
Dyspepsia, Gastro-oesophageal reflux disease
Adult: Per tablet/capsule contains pantoprazole 40 mg and domperidone 10 mg: 1 tablet/capsule once daily.
Contraindications
Pantoprazole: Hepatic impairment; hypersensitivity. Domperidone: History of hypersensitivity to dimenhydrinate or related compounds; GI haemorrhage, obstruction and perforation, or after surgery, pregnancy.
Special Precautions
Lactation. Pantoprazole: Not recommended in child <12 yrs. Long-term therapy may lead to bacterial overgrowth in the GIT. Domperidone: Increases serum prolactin levels resulting to galactorrhoea in females and gynaecomastia in males. Hypertensive crisis in patients with phaeochromocytoma.
Adverse Reactions
Pantoprazole: Diarrhoea, dizziness, pruritus, skin rashes, GIT infections; anaphylaxis, angioedema, chest pain, dyspnoea, erythema multiforme, gastroenteritis, hyperglycaemia, infection, Inj site reaction, jaundice, optic neuropathy, anterior ischaemia, pancreatitis, speech disorder. Domperidone: Headache, insomnia, nervousness, dizziness, thirst, lethargy, irritability, GI disturbances, hot flushes, mastalgia, galactorrhoea, gynaecomastia, menstrual irregularities, rash, pruritus, urticaria, stomatitis, conjunctivitis, urinary frequency, dysuria, oedema, palpitations, leg cramps, asthaenia, drug intolerance.
Drug Interactions
Care should be exercised when domperidone is administered in combination with MAO inhibitors.
Action
Pantoprazole acts by selectively inhibiting the H+/K+-ATPase enzyme in the secretory canaliculus of the stimulated parietal cell. Domperidone stimulates GI activity by acting as a competitive antagonist at dopamine D2-receptors.
ATC Classification
A02BC02 - pantoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
A03FA03 - domperidone ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.
Disclaimer: This information is independently developed by CIMS based on pantoprazole + domperidone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in